Abstract
Introduction: The N2 /IIIA Non small cell Lung cancer is a heterogenous group of patients with many differences within the stage that warrant different treatment strategies and have an individual prognosis that varies depending on the size, site and number of lymph node stations involved. Method: Review of the pertinent current literature on the identification of the various subsets of N2 disease and their management and prognosis. Discussion: Define the spectrum of N2 disease and characterize the subsets within the stage. Highlight the different management strategies and prognosis of the various N2 scenarios that are commonly seen. Examine the evidence for restaging after neoadjuvant therapy and the modalities that may be used. Summary: A concise outline of the subsets within the N2/IIIA stage with their evidence based treatment and survival.
Keywords: Ipsilateral mediastinal lymph node, positron emission tomography, Computed tomography scanning, endoscopic ultrasound, N2 Disease, Platinum-based therapy
Current Cancer Therapy Reviews
Title: Stage N2/IIIA Non Small Cell Lung Cancer: An Evidence-Based Review
Volume: 3 Issue: 2
Author(s): Christopher B. Komanapalli, Charles R. Thomas and Mithran S. Sukumar
Affiliation:
Keywords: Ipsilateral mediastinal lymph node, positron emission tomography, Computed tomography scanning, endoscopic ultrasound, N2 Disease, Platinum-based therapy
Abstract: Introduction: The N2 /IIIA Non small cell Lung cancer is a heterogenous group of patients with many differences within the stage that warrant different treatment strategies and have an individual prognosis that varies depending on the size, site and number of lymph node stations involved. Method: Review of the pertinent current literature on the identification of the various subsets of N2 disease and their management and prognosis. Discussion: Define the spectrum of N2 disease and characterize the subsets within the stage. Highlight the different management strategies and prognosis of the various N2 scenarios that are commonly seen. Examine the evidence for restaging after neoadjuvant therapy and the modalities that may be used. Summary: A concise outline of the subsets within the N2/IIIA stage with their evidence based treatment and survival.
Export Options
About this article
Cite this article as:
Komanapalli B. Christopher, Thomas R. Charles and Sukumar S. Mithran, Stage N2/IIIA Non Small Cell Lung Cancer: An Evidence-Based Review, Current Cancer Therapy Reviews 2007; 3 (2) . https://dx.doi.org/10.2174/157339407780618416
DOI https://dx.doi.org/10.2174/157339407780618416 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Enjoy the Silence: The Story of let-7 MicroRNA and Cancer
Current Genomics Synthesis and Biological Activities of Naturally Functionalized Polyamines: An Overview
Current Medicinal Chemistry Synthesis and Biological Evaluation of Novel 4,5,6,7-Tetrahydrobenzo[D]-Thiazol-2- Yl Derivatives Derived from Dimedone with Anti-Tumor, C-Met, Tyrosine Kinase and Pim-1 Inhibitions
Anti-Cancer Agents in Medicinal Chemistry The Role of Estrogen and Estrogen Receptors in Chemoresistance
Current Medicinal Chemistry Geriatric Evaluation of Oncological Elderly Patients
Anti-Cancer Agents in Medicinal Chemistry Esophagitis, Treatment-Related Toxicity in Non-Small Cell Lung Cancer
Reviews on Recent Clinical Trials Separating Fact from Fiction: Assessing the Potential of Modified Adenovirus Vectors for Use in Human Gene Therapy
Current Gene Therapy (Review Article) Screening for Disease-Markers and Investigating Drug Effects by Proteome Profiling: Can it Meet Expectations?
Combinatorial Chemistry & High Throughput Screening Controlling Receptor Downregulation by Ubiquitination and Deubiquitination
Current Drug Discovery Technologies Vitiligo: An Updated Narrative Review
Current Pediatric Reviews Pharmacotherapy in Systemic Lupus Erythematosus
Current Rheumatology Reviews Heat Shock Protein (HSP) Drug Discovery and Development: Targeting Heat Shock Proteins in Disease
Current Topics in Medicinal Chemistry Development of Arene Ruthenium Antitumor Complexes
Mini-Reviews in Medicinal Chemistry Genetic and Pharmacogenetic Aspects of Alcohol-Dependence
Current Pharmacogenomics Physiologically Based Mathematical Models to Optimize Therapies Against Metastatic Colorectal Cancer: A Mini-Review
Current Pharmaceutical Design Potential Utilization of Bystander / Abscopal-Mediated Signal Transduction Events in the Treatment of Solid Tumors
Current Signal Transduction Therapy MicroRNAs Patents: The Road From Bench to Bedsides for Cancer Treatment
Recent Patents on DNA & Gene Sequences Induction of Apoptosis and Sensitization of Head and Neck Squamous Carcinoma Cells to Cisplatin by Targeting Survivin Gene Expression
Current Gene Therapy α-Halogenoacrylic Derivatives of Antitumor Agents
Mini-Reviews in Medicinal Chemistry